Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SlimAmerica Super Formula weight loss products target of FTC suit.

This article was originally published in The Tan Sheet

Executive Summary

SLIMAMERICA ORDERED TO HALT BUSINESS: SUPER FORMULA WEIGHT LOSS PRODUCTS advertising claims are "false and misleading," the Federal Trade Commission charged Feb. 3 after filing suit Jan. 24 against SlimAmerica. A temporary restraining order issued by a Miami federal court also freezes the assets of the Deerfield Beach, Fla.-based company. FTC's request to permanently enjoin SlimAmerica is scheduled for a hearing on Feb. 10.

You may also be interested in...



Sarcona convicted in supplement scam

A federal jury convicts Frank Sarcona, a Boca Raton, Fla., businessman of defrauding more than 100,000 consumers out of more than $16 million "through his fraudulent sales techniques" relating to a supplement product called Lipoban, says Jeffrey Sloman, U.S. Attorney for the Southern District of Florida. Sarcona's sentencing is scheduled for Jan. 15, 2010. Sloman's Oct. 30 release says Sarcona - also known as Frank Sarcone and Dave Johnson - violated a 1999 final injunction order prohibiting his connection with the sale of a supplement and requiring him to post a $5 million performance bond before becoming involved with a weight-loss service or product. The injunction order stemmed from the lawsuit FTC v. SlimAmerica (1"The Tan Sheet" Feb. 10, 1997)

Sarcona convicted in supplement scam

A federal jury convicts Frank Sarcona, a Boca Raton, Fla., businessman of defrauding more than 100,000 consumers out of more than $16 million "through his fraudulent sales techniques" relating to a supplement product called Lipoban, says Jeffrey Sloman, U.S. Attorney for the Southern District of Florida. Sarcona's sentencing is scheduled for Jan. 15, 2010. Sloman's Oct. 30 release says Sarcona - also known as Frank Sarcone and Dave Johnson - violated a 1999 final injunction order prohibiting his connection with the sale of a supplement and requiring him to post a $5 million performance bond before becoming involved with a weight-loss service or product. The injunction order stemmed from the lawsuit FTC v. SlimAmerica (1"The Tan Sheet" Feb. 10, 1997)

Sarcona convicted in supplement scam

A federal jury convicts Frank Sarcona, a Boca Raton, Fla., businessman of defrauding more than 100,000 consumers out of more than $16 million "through his fraudulent sales techniques" relating to a supplement product called Lipoban, says Jeffrey Sloman, U.S. Attorney for the Southern District of Florida. Sarcona's sentencing is scheduled for Jan. 15, 2010. Sloman's Oct. 30 release says Sarcona - also known as Frank Sarcone and Dave Johnson - violated a 1999 final injunction order prohibiting his connection with the sale of a supplement and requiring him to post a $5 million performance bond before becoming involved with a weight-loss service or product. The injunction order stemmed from the lawsuit FTC v. SlimAmerica (1"The Tan Sheet" Feb. 10, 1997)

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS086683

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel